Skip to content

Cognitive Behaviour Therapy for Patients With IBS

Cognitive Behavior Therapy (CBT) as Compared With Standard Therapy for Patients With IBS and Other Functional Gastrointestinal Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00788658
Acronym
EFI
Enrollment
100
Registered
2008-11-11
Start date
2008-12-31
Completion date
2010-12-31
Last updated
2016-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Pain, Constipation, Depression, Irritable Bowel Syndrome

Keywords

Obstructed constipation, Quality of life

Brief summary

Irritable bowel syndrome (IBS) affects approximately 10-15% of the adult population. This condition is characterized by abdominal pain, altered bowel habit, abdominal bloating and reduced quality of life. Options for treating IBS include pharmacotherapy, psychotherapy, hypnotherapy and cognitive behavior therapy (CBT). Available data on the effectiveness of CBT in IBS patients in Israel are scarce. The aim of the present study is to assess effectiveness of CBT as compared with standard therapy for IBS patients in Israel The course of CBT consisted of up to six 40 min sessions, and included education about IBS and techniques to reduce focusing on symptoms and to manage stress.Standard therapy includs life style modifications. The primary outcome measure was the score on a symptom-severity scale specific to IBS.

Detailed description

Symptomatic treatment of patients would not be modified

Interventions

BEHAVIORALDiet modifications

Diet consultation

BEHAVIORALCognitive behavioral therapy

Cognitive behavioral therapy

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 * IBS

Exclusion criteria

* Malignancy * Known psychiatric disorders

Design outcomes

Primary

MeasureTime frame
Symptom score3 months

Secondary

MeasureTime frame
Quality of life assessment3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026